AcetazolamideWorsening acidosis following an off-label use: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1821卷 / 1期

关键词：

D O I：

10.1007/s40278-020-83134-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：14 / 14

相关论文

共 50 条

[1] TopiramateHyperchloraemic acidosis and pancreatitis following an off-label use of topiramate: 2 case reports
[J]. Reactions Weekly, 2020, 1787 (1) : 466 - 466
[2] FerumoxytolNausea following off-label use: 2 case reports
[J]. Reactions Weekly, 2017, 1650 (1) : 142 - 142
[3] BebtelovimabAnaphylaxis following off-label use: 2 case reports
[J]. Reactions Weekly, 2023, 1954 (1) : 113 - 113
[4] UstekinumabMyositis following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1870 (1) : 306 - 306
[5] BevacizumabEndophthalmitis following off-label use: 2 case reports
[J]. Reactions Weekly, 2019, 1757 (1) : 64 - 64
[6] SarilumabNeutropenia following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1921 (1) : 255 - 255
[7] ClozapineAgranulocytosis following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1924 (1) : 164 - 164
[8] TriamcinoloneOcular hypertension following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1917 (1) : 567 - 567
[9] OsimertinibFrailty and pneumonitis following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1905 (1) : 406 - 406
[10] PembrolizumabHepatotoxicity and erythema following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1900 (1) : 270 - 270

← 1 2 3 4 5 →